Literature DB >> 26211418

5-aminomethyloxazolidine-2,4-dione hybrid α/β-dipeptide scaffolds as inductors of constrained conformations: Applications to the synthesis of integrin antagonists.

Rossella De Marco1, Giacomo Mazzotti1, Samantha D Dattoli2, Monica Baiula2, Santi Spampinato2, Arianna Greco1, Luca Gentilucci1.   

Abstract

Peptidomimetics represent an attractive starting point for drug discovery programs; in particular, peptidomimetics that result from the incorporation of a heterocycle may take advantage of increased enzymatic stability and higher ability to reproduce the bioactive conformations of the parent peptides, resulting in enhanced therapeutic potential. Herein, we present mimetics of the α4β1 integrin antagonist BIO1211 (MPUPA-Leu-Asp-Val-Pro-OH), containing a aminomethyloxazolidine-2,4-dione scaffold (Amo). Interestingly, the retro-sequences PhCOAsp(OH)-Amo-APUMP including either (S)- or (R)-configured Amo displayed significant ability to inhibit the adhesion of α4β1 integrin expressing cells, and remarkable stability in mouse serum. Possibly, the conformational bias exerted by the Amo scaffold determined the affinity for the receptors. These peptidomimetics could be of interest for the development of small-molecule agents effective against inflammatory processes and correlated autoimmune diseases.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  conformational analysis; freidinger lactam; integrin inhibitor; jurkat cells; β2-amino acid

Mesh:

Substances:

Year:  2015        PMID: 26211418     DOI: 10.1002/bip.22704

Source DB:  PubMed          Journal:  Biopolymers        ISSN: 0006-3525            Impact factor:   2.505


  3 in total

1.  DS-70, a novel and potent α4 integrin antagonist, is an effective treatment for experimental allergic conjunctivitis in guinea pigs.

Authors:  Samantha Deianira Dattoli; Monica Baiula; Rossella De Marco; Andrea Bedini; Michele Anselmi; Luca Gentilucci; Santi Spampinato
Journal:  Br J Pharmacol       Date:  2018-09-17       Impact factor: 8.739

2.  Leukocyte Integrin Antagonists as a Novel Option to Treat Dry Age-Related Macular Degeneration.

Authors:  Monica Baiula; Alberto Caligiana; Andrea Bedini; Junwei Zhao; Federica Santino; Martina Cirillo; Luca Gentilucci; Daria Giacomini; Santi Spampinato
Journal:  Front Pharmacol       Date:  2021-01-29       Impact factor: 5.810

3.  Development of New Potential Inhibitors of β1 Integrins through In Silico Methods-Screening and Computational Validation.

Authors:  Disraeli Vasconcelos; Beatriz Chaves; Aline Albuquerque; Luca Andrade; Andrielly Henriques; Geraldo Sartori; Wilson Savino; Ernesto Caffarena; João Herminio Martins-Da-Silva
Journal:  Life (Basel)       Date:  2022-06-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.